Introduction:
Acute lymphoblastic leukemia (ALL) is the most common malignancy among children. It has a good prognosis after regular treatment. However, the current treatment of this disease has encountered certain challenges, one of which is the side effects of chemotherapy drugs associated with treatment intolerance, including chemotherapy-related pancreatitis. Asparaginase is significantly associated with pancreatitis, which is important for the treatment of lymphocytic leukemia and can significantly improve prognosis. However, the use of asparaginase may be restricted by the occurrence of drug-induced pancreatitis, which may result in serious infection, disorder of circulation, pancreatic injury and multiple organ dysfunction, and may also affect the prognosis of ALL. [1-3]
Many studies have shown that the incidence of asparaginase-associated pancreatitis varies from 1.5% to 18%,[4-8] and have explored the risk factors for pancreatitis in patients receiving chemotherapy, such as age and the cumulative dosage of asparaginase, etc. But there are still other drugs associated with pancreatitis and possible risk factors. Assessment before chemotherapy of the risk of pancreatitis may be good for preventing pancreatitis from happening, and improving the prognosis of ALL. This study seeks to develop a tool that can predict the risk of pancreatitis in children with leukemia treated with the China Children’s Leukemia Group(CCLG)-ALL regimen, potentially aiding in early detection and intervention.